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Present Perspectives
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Ahmed Abdellatif and Waheed K. Zahra
Abstract
Duchenne muscular dystrophy (DMD) is one of the fatal X-linked disorders 
that are characterized by progressive muscle weakness and occur due to mutation 
in the largest human gene known as the DMD gene which encodes dystrophin 
protein that is mandatory for keeping the muscles structurally and functionally 
intact. The disease always affects boys (1 from every ~5000), and in some cases the 
female carriers are symptomatic. The disease usually leads to impairment in cardiac 
and pulmonary functions leading to the death of the patients in very young ages. 
Understanding DMD through precise molecular diagnosis will aid in determining 
the suitable therapeutic approach for the cases like designing exon-skipping anti-
sense oligonucleotides (AOs) or stem cell-based therapies in conjunction with gene 
editing techniques (CRISPR/Cas9). Such therapies can correct the genetic defect in 
the DMD gene and ameliorate the symptoms. In this chapter, we will illustrate the 
past and current strategies for DMD disease treatment.
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1. Introduction
Duchenne muscular dystrophy (DMD) is a fatal X-linked disorder characterized 
by skeletal muscle wasting that is resulted from mutations in the dystrophin gene 
[1]. The disease occurs at a frequency of about 1 in ~5000 newborn males, making it 
the most common severe neuromuscular disease in humans. Dystrophin is present 
in normal individuals from fetal life onwards in all skeletal, cardiac, and smooth 
muscles; the absence of dystrophin protein causes muscle weakness and protein 
degradation and ultimately causes cell death. Death usually occurs in the third 
decade of life as the result of respiratory or heart failure [2]. The precise diagnosis 
for DMD should contain a combination of genetic testing after muscle biopsy and 
clinical observation of muscle strength and function.
The main current medication so far is corticosteroids, which have been shown 
to increase muscle strength in many studies. Genetic therapy using mini-/micro-
dystrophin vectors, suppression of premature termination codon, exon-skipping 
antisense oligonucleotides (AOs) which bind with RNA and exclude specific sites of 
RNA splicing producing a dystrophin that is smaller but functional, and such new 
emerging drugs are the pass to the new era towards DMD treatment. In the next 
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section, we will review all available FDA-approved treatments and recent research 
trials aiming at ameliorating DMD symptoms.
2. Methods for treatment
2.1 Corticosteroids
Corticosteroids were the first line of treatment for DMD; it was first used by 
Drachman et al. in 1974 [3] when they had promising positive results in their study 
after using prednisone (anti-inflammatory glucocorticosteroid). Since then, many 
studies were carried out to test the therapeutic effect of such treatment since it was 
found to improve muscle performance.
Deflazacart (DFZ), an oxazolidine derivative of prednisone, was used by an 
Italian group [4] and other groups [5–7], and the drug demonstrated efficiency in 
disease treatment and preserved lung function. The exact mechanism of DFZ is 
not yet known; however, it might regulate some signaling cascades. It was found to 
activate calcineurin/NF-AT pathway [8]. Also, DFZ may act by decreasing necrosis 
and muscle inflammation and reducing the degree of muscle degeneration. It can 
also act through modulating dystrophin expression and inducing the myogenesis in 
addition to having positive effects on muscular tissue mass [9].
Despite the advantages of using steroids, they also had side effects like gain-
ing weight, affecting bone mineral density, which leads to vertebral fractures and 
behavioral changes. Furthermore, high dosages are required to reach the target 
effect and to be active at the site inflammation. Also, the drug can be accumulated 
in other nontargeted areas [10, 11].
In one of their studies, Luhder et al. [12] tried to improve the therapeutic effect 
of the steroids through developing an 80 nm PEGylated nano-liposome that is con-
jugated with the steroid prodrug “methylprednisolone hemisuccinate.” The results 
of their study showed that such structure was selectively targeting the diaphragm 
in vivo (using mdx mouse model) when administered intravenously and the treat-
ment reduced the infiltration with macrophages and serum levels of transforming 
growth factor beta. Most importantly, the study showed that long-term use of this 
formulation leads to enhanced mobility and increased muscle strength.
2.2 Exon skipping
Exon skipping is considered as one of the mutation-based treatments for 
Duchenne muscular dystrophy [13]. In DMD, some deletions in specific exons lead 
to the disruption of the reading frame of the dystrophin protein, and consequently 
such deletions lead to the production of truncated product missing a huge part of 
the protein (usually missing the rod domain and C-terminal domain).
However, sometimes, deleting additional exons may restore the reading frame 
and lead to the production of dystrophin protein missing only a portion of the 
central rod domain while the C-terminal domain remains intact, and hence the 
protein product in this case is lacking specific regions, but it is semi-functional 
and can induce Becker-like symptoms instead of the complete loss of the muscular 
function [14].
The main idea of exon skipping is using the “antisense oligonucleotide” mol-
ecules to induce the skipping of a specific exon (other than the already mutated 
one) and prevent it from being translated to restore the reading frame. As an 
example, patients with exon 45 deletion could be treated through the skipping of an 
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additional exon 44. Eteplirsen (Exondys51™) based on phosphorodiamidite mor-
pholino oligomer (PMD) is an FDA-approved antisense treatment to skip exon 51 
for patients with mutation ▲49–50 [15]. Also, drisapersen (based on 2′-O-methyl 
phosphorothioate; 2′-OMePS-modified AOs) is one of the AOs that are designed to 
treat DMD patients with mutations that can be ameliorated by exon 51 skipping; 
however it was not approved by the FDA [16, 17].
Various modifications can take place to the sugar of the oligonucleotide or to the 
backbone of the oligo. This could include phosphorodiamidate morpholino, locked 
nucleic acid (LNA), or peptide-conjugated oligo. Regarding the morpholinos, the 
oligonucleotide backbone is replaced with the morpholino backbone which makes 
the oligonucleotide nontoxic and has high affinity to RNA molecules. The locked 
nucleic acids are oligonucleotides that have a modified ribose sugar where the 2′ 
oxygen is connected with the 4′ carbon atom which creates a locked ribose ring. 
Also, the LNAs are nontoxic with superior affinity to complementary targeted RNA 
sequences [18].
The main problem in developing such treatments based on the skipping is that it 
will only fit a small group of patients (a mutation-specific AO should be developed 
for each group of patients and will not be suitable for other patients); also some 
patients have deletions in critical parts of the protein, and hence skipping of other 
exons will not have a therapeutic impact (Table 1).
2.3 Induced pluripotent stem cells along with genome editing technique
The sole cause of DMD is the presence of mutation that adversely affects the DMD 
gene. So, in order to permanently fix such mutations and treat this condition, patients 
could be provided with muscle cells harboring the normal copy of DMD gene. Since 
it is hard to get mature muscle fibers from a normal individual to be used as a source 
of healthy muscle cells with normal DMD gene, also the availability of such source of 
cells will not guarantee the process of grafting in the patient’s muscles since it could 
be subjected to rejection by the body and can initiate an aggressive immune response. 
Cell reprogramming and genome editing techniques efficiently aid in solving this 
puzzling dilemma [25]. The process of cell reprogramming paved the road towards 
developing normal muscle fibers by starting with patient-specialized adult cells 
followed by inducing the production of induced pluripotent stem cells (iPSCs) (using 
the Nobel prize-winning technology of reprogramming using specific transcrip-
tion factors like Oct4, Sox2, Klf4, and L-Myc) [26]. Also, some microRNAs have the 
potential to reprogram the adult cells efficiently (like miR-302b, miR-372) [27].
After the reprogramming and the production of stem cells, gene editing tech-
nologies should be used to correct the mutation of the gene. CRISPR/Cas 9 is now 
a leading technology that is presently considered as an avenue for DMD treatment; 
the RNA-guided DNA endonuclease system allows the correction of the DMD seg-
ment which is essential for dystrophin restoration [28, 29].
In order to conduct a gene editing experiment with CRISPR/Cas9 system, two 
important elements should be provided: guide RNA (gRNA) specific for the target 
gene and Cas9 nuclease (Sp. Cas9 (from Streptococcus pyogenes; 4.10 kb) or Sp. Cas9 
(Staphylococcus aureus; 3.16 kb)) or Cj. Cas9 (Campylobacter jejuni; 2.95 kb) that can 
cleave DNA strands where the guide RNA is bound and in the presence of three- to 
five-nucleotide proto-spacer adjacent motif (PAM) sequence to be digested. Upon 
the binding of the gRNA, Cas9 can induce a double-strand break which is then 
repaired by the cell through the nonhomologous end joining, and this will initiate a 
repair mechanism in which nucleotides will be added or deleted at the cleaved site 
which can consequently restore the reading frame of the DMD gene to the normal 
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Chemistry Route of 
administration
The used model Treatment 
strategy
Treatment effects Reference
Phosphorodiamidate morpholino 
oligomers (Ex6A, Ex6B, Ex8A, and 
Ex8G)
Intravenous Neonatal CXMDJ Exon 6–9 
skipping
Dystrophin restoration across skeletal 
muscles (14% of healthy levels)
Reduction of fibrosis and/or necrosis area
[19]
Phosphorodiamidate morpholino 
oligomer (NS-065/NCNP-01)
Endo-Porter 
reagent
Fibroblasts from patients with DMD 
involving deletion of exons 45–52 or exons 
48–52 and injected with MYOD for myotube 
differentiation
Exon 53 
skipping
Restored dystrophin protein levels in the 
cells
[20]
Phosphorodiamidate morpholino 
oligomer
Intramuscular and 
intravenous
mdx52 mouse model Exon 51 
skipping
Only the protocol was mentioned [21]
Phosphorodiamidate morpholino 
oligomer (NS-065/NCNP-01)
Intravenous Patients with DMD Exon 53 
skipping
Increased dystrophin/spectrin ratio in 7 of 
10 patients in TA muscle biopsies
[22]
Pip6a-PMO; PMOME23, sequence 
GGCCAAACCTCGGCTT-
ACCTGAAAT
Intravenous Cmah-/-mdx mice Exon 23 
skipping
Dystrophin restoration in the heart
Reduction in myocardial fibrosis
Reducing maximum pressure and arterial 
elastance
[23]
Inhibitor of CDC2-like kinase 1 
(named TG693)
Oral
Lipofectamine 
reagent
Male Jcl:TCR mice
Patient-derived myotubes
Exon 31 
skipping
It induces exon skipping and restored 
dystrophin expression in patient-derived 
cells. And it modulated splicing in mouse 
skeletal muscle
[24]
Morpholino AOs targeting DMD 
exon 51
Endo-Porter 
transfection
Intramuscular
Immortalized DMD muscle cells
hDMD/Dmd null mice
Exon 51 
skipping
The rescue of dystrophin protein 
expression
[25]
Table 1. 
Studies conducted on treatment of DMD using exon skipping (during 2017–2019).
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ORF. In some cases, single (or several) gRNA molecule could be designed to target 
splicing sites which can lead to the skipping of specific exon leading to the produc-
tion of functional proteins. Additionally, base editing mediated by CRISPR/Cas9 
could be obtained through Cas9 enzymes lacking the nuclease activity, so it can 
induce only a single-strand break. Such enzymes can catalyze base editing (A:T to 
G:C) through having a cytidine deaminase activity [30].
Ousterout et al. in their study used another editing protocol (zinc finger nucle-
ase) to delete exon 51 from the transcript from patient-derived myoblasts [31]. Also, 
Young et al. carried out CRISPR/Cas9 experiment utilizing a single pair of guide 
RNAs to delete exons 45–55 in iPSC, and such deletion leads to the expression of 
stable dystrophin protein with improved membrane stability in derived skeletal 
myotubes and cardiomyocytes [32]. Another study by Duchene et al. utilized a sin-
gle guide RNA to produce a hybrid exon which led to the production of functional 
dystrophin protein with completely normal structure [33]. The main advantage of 
this reprogramming protocol is that it allows performing an autologous grafting of 
the muscle cells to patients.
For the expression of the specific gRNA molecules inside the muscle cells, 
adeno-associated virus (AAV) vectors will be used. Sometimes, the expression of 
the gRNAs can lead to off-target effect due to the incorrect binding with another 
similar DNA sequence inside the host cell. In order to avoid this damaging effect, 
AAV vectors expressing multiple gRNA molecules could be used.
After the completion of the gene editing process, the edited cells would be 
treated with myogenic factors to convert the edited stem cells again to myoblasts for 
the myogenic differentiation (Table 2).
2.4 Gene therapy
Gene therapy is one of the most appealing techniques that are used to deliver a 
normal copy of the DMD gene to express the fully functional dystrophin protein. 
This method implies injecting the patients with plasmids carrying normal dystro-
phin cDNA (~12 kb).
In 2002, the first phase 1 trial of DMD gene therapy took place using full-length 
dystrophin [52]. After that, adeno-associated viral vectors carrying mini forms of 
dystrophin cDNA were used for gene therapy, and this was better regarding the 
packaging size of the plasmids, and it is much easier to transfer/deliver mini forms 
of DMD gene [53, 54].
However, such therapeutic approach faced another problem which is the distri-
bution of the plasmids across all affected muscular tissue that is spreading all over 
the body, and that is why microdystrophin plasmids and systemic AAV delivery 
were developed and improved to solve such problem. Evidence from many trials 
using animal models revealed that gene therapy can lead to long-term expression of 
functional protein [55–57].
In 2017, Le Guiner et al. studied the effect of the delivery of rAAV2/8 vector 
expressing a canine microdystrophin (cMD1) in golden retriever muscular dystro-
phy (GRMD) dogs in the absence of immunosuppression. Such treatment affected 
the deterioration of the muscular activity, and the gene expression was maintained 
over a long period [56]. Recently in 2020, Genthon and Sarepta contracted Yposkesi 
for manufacturing the AAV microdystrophin vector on a large scale.
2.5 Dystrophin-expressing chimeric cells
As previously mentioned, the absence of dystrophin is the main cause of DMD 
disease and the aggressive symptoms including muscle weakness and degeneration 
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Plasmids (source of Cas9 and guide RNAs) Route of administration The used model Treatment 
strategy
Reference
Adeno-associated viral vectors of serotype 9 carrying an intein-
split Cas9
A pair of guide RNAs targeting sequences flanking exon 51 
(AAV9-Cas9-gE51)
Intramuscular injection DMDΔ52 pigs Excision of exon 51 [34]
SaCas9 expression plasmid
Two gRNA expression cassettes driven by the human U6 pol. III 
promoter
(AAV8 and AAV9)
Locally in the TA muscles C57BL/10ScSn-Dmdmdx/J Excision of exon 23 [35]
pSpCas9 expression plasmid
AAV TRISPR-sgRNA-CK8e-GFP plasmid contained three
sgRNAs driven by the U6, H1, or 7SK promoter and green 
florescent protein (GFP) driven by the CK8e regulatory cassette
Transfection reagent
Locally in the TA muscles
Human DMD-derived iPSCs
▲Exon 44 DMD mice
Excision of exons 
43 and 45
[36]
Streptococcus pyogenes Cas9
Single guide RNA (sgRNA-51)
(AAV9-Cas9 and AAV9-sgRNA-51)
Locally in the cranial tibialis 
muscles
▲Exon 50 canine model Excision of exon 51 [37]
spCas9 and crDMDint2.1 and int2.6 gRNAs Transfection reagent (linear 
polyethylenimine derivative)
Immortalized myoblasts from DMD patient Excision of 
duplicated exon 2
[38]
Lenti-V2-Ugi-nCas9-AIDx or Lenti-V2-AIDx-nSaCas9 (KKH)-
Ugi (2.5 μg) and pCDNA3 Ugi
Transfection reagent 
(lipid-based)
▲51-iPSCs of a male DMD patient Excision of exon 
50
[39]
CRISPR-Cas9 variant (D10A Cas9 nickase (nCas9) or 
catalytically deficient D10A/H840A Cas9 (dCas9) from S. 
pyogenes) and a deaminase protein from various sources
sgRNA (gX20) under the control of the U6 promoter 
(pAAV-ITR-ABE-NT-sgRNA)
Micromanipulator Mouse zygote from DMD knockout mouse Base editing of 
exon 20
[40]
Plasmids containing regulatory cassettes for expression of Cas9 
or gRNAs flanked by AAV serotype 2 inverted terminal repeats
(ITRs)
Electroporation
Intramuscular
Fibroblasts isolated from male mdx4cv mice
Male mdx4cv mice
Excision of exons 
52 and 53
[41]
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Plasmids (source of Cas9 and guide RNAs) Route of administration The used model Treatment 
strategy
Reference
pX601-AAV CMV::NLS-SaCas9-NLS-3xHA-bGHpA;U6::BsaI-
sgRNA (PX601)
Transfection reagent 
(lipid-based)
Myoblasts Excision of exons 
47 and 48
[33]
DMD iPSC Excision of exons 
44–55
[32]
The gRNA cassettes gI43, gI52, gI53, and gI54.2 (targeting 
different introns) controlled by human U6 RNA polymerase III 
promoter
Plasmids AU53_pAd
Shu.gI52.gI53.PGK.Cas9.SV40pA, plasmids pLV.gI52 and pLV.
gI53
Transduction (by gelatin) DMD myoblasts Δ48–50 and Δ45–52 Excision of exon 53 [42]
pAAV-ITR-CjCas9-sgRNA, pAAV2/9 encoding for AAV2rep and 
AAV9cap, and helper plasmid
Intramuscular in the TA 
muscle
Knockout mice Excision of exon 23 [43]
pSpCas9(BB)-2A-GFP (PX458) Transfection reagent DMD hiPSCs, hiPSC-derived cardiac muscle cells Excision of exon 
51, introns 47, 
50, 54
[44]
pSpCas9(BB)-2A-GFP (PX458) Intramuscular in the TA 
muscle
Mice ▲50 Excision of exon 51 [45]
Purified Cas9 protein and in vitro transcribed gRNA Gold nanoparticles Primary myoblasts C57BL/10ScSn-Dmdmdx/J 
(mdx) mice
Excision of exon 23 [46]
pSpCas9(BB)-2A-GFP (PX458) Nucleofection Induced pluripotent stem cells (iPSCs) Deleting exons 
3–9, 6–9, or 7–11
[47]
Nuclease-expressing plasmids (TALENs, left and right; CRISPR, 
Cas9 and sgRNA)
Electroporation DMD fibroblasts were derived from a DMD 
patient lacking exon 44
Excision of exon 45 [48]
Cas9 mixed with 44C1, 44C2, 45C2, and 45C3 gRNAs produced 
via in vitro transcription
Electroporation hDMD (Tg(DMD)72Thoen/J, 018900), 
C57BL/10 mdx (001801), and mdxD2 (D1.
B10-Dmdmdx/J, 013141)
Excision of exons 
45–55
[49]
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Plasmids (source of Cas9 and guide RNAs) Route of administration The used model Treatment 
strategy
Reference
AdV-Cas9-RFP
AdG-gRNA-Donor
Transfection reagent (lipid 
based)
Skeletal muscle cell culture derived from 
C57BL/10ScSn-Dmd mdx/J
Excision of exon 23 [50]
Cpf1 gRNAs targeting the human DMD or the mouse Dmd locus 
(subcloned into pLbCpf1-2A-GFP and pAsCpf1-2A-GFP)
Nucleofection DMD iPSC cells Excision of exon 51 [51]
Table 2. 
Studies conducted on treatment of DMD using gene editing techniques (CRISPR/Cas9) (during 2017–2020).
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of muscle fibers. Such defect in the DMD gene can be edited using gene editing 
technology; however such technology can lead to off-target mutations which 
consequently can have damaging effects, and that is why more therapies had to be 
developed to address the disadvantages of such techniques.
Chimeric cell therapy is an alternative therapeutic approach that is usually 
done through the fusion of normal myoblasts and dystrophin-deficient myoblasts 
using polyethylene glycol (PEG). The success of this process could be tested using 
immunophenotyping (flow cytometry) and dystrophin immunostaining. This 
fusion will be followed by transplantation of chimeric cells in the defected muscle. 
The chimeric cells always show behavior like the donor cells regarding dystrophin 
expression and myogenic differentiation, and this dramatically improves the muscle 
function after being transplanted [58].
2.6 Cardiosphere-derived cells (CDCs)
Cardiosphere-derived cells are a type of cells that are retrieved from cardiac 
explants that can be cultured in vitro. Such cells have anti-inflammatory, antioxi-
dant, and antibiotic activities. Several studies tested the ability of CDCs to alter the 
pathophysiology of DMD after the injection of these cells directly into the cardiac 
muscle.
Recently it was found that using CDCs greatly enhanced the phenotypic status 
of cardiac and skeletal muscles. The therapeutic effects of CDCs are usually attrib-
uted to the secretion of specific exosomes carrying specific genetic material to distal 
cells to exert its biological effect. Such CDCs along with their secreted exosomes can 
be injected intravenously, and it was found that they can greatly enhance the skel-
etal and cardiac muscle functions and boost the muscle generation process [59, 60].
2.7 Stop codon read-through therapy
In some of the mutations affecting the DMD gene, a premature stop codon is 
produced that can significantly disturb the reading frame and gives a truncated 
abnormal protein that cannot maintain the structural and functional properties of 
the muscle fibers.
A class of antibiotics called aminoglycosides was found to bind to rRNA at their 
decoding sites, preventing the stop codons from being read by binding to the A 
site (acceptor site) in the ribosomes and forcing the cell to prevent reading the stop 
codon, hence leading to the production of fully functional proteins.
PTC124 (ataluren; trade name, Translarna™) is one of the drugs with the read-
through properties that are used for the treatment of DMD. Clinical trials showed 
that this drug when administered orally induced the expression of the dystrophin 
protein.
However, this treatment can only be used in ~15% of the cases who have a stop 
signal resulted from point mutation in the DMD gene. Also, it must be administered 
in increasing doses; beside it has many side effects such as renal toxicity. That is why 
there is a need to develop other alternatives with other structures to be safer with 
chronic usage.
2.8 Utrophin modulation
Recently, DMD symptoms were found to be managed after the administration of 
utrophin protein expression enhancers (utrophin is a dystrophin homolog; 395 KDa 
in size) to DMD patients delays the need of wheelchair and efficiently substitutes 
non-functional dystrophin.
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Like dystrophin, the utrophin is present in the sarcolemma in the first develop-
mental stages, and then replacement with dystrophin took place during muscular 
maturation. However, utrophin was found to be present in the myotendinous 
junction in adults. Interestingly, the expression of utrophin becomes elevated as a 
normal repair mechanism to compensate the absence of functional dystrophin in 
regenerated muscles.
SMTC-1100 is one of the chemical molecules that showed a great potential 
to increase the expression of DMD transcript and protein as well. This drug can 
be administered orally, if it was found to be safe and well tolerated in volunteers. 
However further studies are still required to detect if high dosage of this drug is 
safe or not.
Recently, ASA or adenylo-succinic acid improved the status of the TA muscles in 
mdx mice after administration of this compound in the drinking water. This mol-
ecule regulated the expression of the utrophin protein and hence greatly reduced 
the damaged area [61].
Another study group designed AAV vector carrying mini forms of the utrophin 
protein (μUtro). Their results showed that expression of this functional copy of 
utrophin protein (dystrophin analogue) after administration of the utrophin vector 
in DMD animal models completely reduced the muscle necrosis and regenera-
tion [62].
3. Conclusion
Many medications have been used for DMD treatment and for preventing 
further deterioration of the cases. Corticosteroids were the first line of effective 
therapy of DMD; however, it does not modify the genetic mutations of the gene 
and does not affect the expression levels of dystrophin protein. Consequently, other 
treatments were developed including read-through stop codon, gene therapies, 
and exon skipping AOs which modulate and upregulate the levels of functional 
dystrophin transcript and protein in the muscles. Genome editing technology is 
also a powerful tool that can treat DMD permanently through the correction of the 
mutated sequence of DMD gene through the administration of sequence-specific 
guide RNA strands to bind selectively in the sequence to be edited. Also upregulat-
ing utrophin can help in the management of the cases. In addition, dystrophin-
expressing chimeric cells and cardiosphere-derived cells are two emerging 
techniques that have the potential to treat DMD. Other medications will be devel-
oped to treat all DMD patients with different mutations with minimum side effects 
and maximum improvement in the status of the muscular system.
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